Przejdź do zawartości
Merck

N0165

Nisoldipine

≥98% (HPLC)

Synonim(y):

(±)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate, 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-methylpropyl ester, Sular

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

10 MG

313,65 zł

50 MG

1530,00 zł

313,65 zł

Cena katalogowa369,00 złZaoszczędź 15%

Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Zamów zamówienie zbiorcze

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C20H24N2O6
Numer CAS:
Masa cząsteczkowa:
388.41
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
264-407-7
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:

Przejdź do

Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc

Quality Level

assay

≥98% (HPLC)

form

powder

color

yellow

solubility

DMSO: >10 mg/mL

originator

Bayer

storage temp.

room temp

SMILES string

COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OCC(C)C

InChI

1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3

InChI key

VKQFCGNPDRICFG-UHFFFAOYSA-N

Gene Information

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 4

Ta pozycja
N75101463508PHR1290
Nifedipine United States Pharmacopeia (USP) Reference Standard

USP

1463508

Nifedipine

form

powder

form

powder

form

-

form

-

assay

≥98% (HPLC)

assay

≥98%

assay

-

assay

-

Quality Level

100

Quality Level

100

Quality Level

-

Quality Level

300

storage temp.

room temp

storage temp.

2-8°C

storage temp.

-

storage temp.

2-30°C

solubility

DMSO: >10 mg/mL

solubility

DMSO: ~1 mg/mL, 0.1 M NaOH: insoluble, H2O: slightly soluble, methanol: soluble

solubility

-

solubility

-

color

yellow

color

yellow

color

-

color

-

Application

Nisoldipine has been used:
  • as a hit-antagonist to study its effects on oxytocin (OT)-induced myometrial Ca2+-mobilization and its potency to dampen uterine myometrial contractions
  • as a calcium channel blocker to study its effects on cell viability in a human hepatic cancer HepG2 and rat renal epithelial NRK52E cell line
  • as a component of the external IK1 recording solution to study the action potential in human pluripotent stem cell−derived cardiomyocytes (hiPS-CMs)

Biochem/physiol Actions

L-type (CaV1.2) calcium channel blocker; dihydropyridine-type calcium channel blocker with selectivity for smooth muscle (CaV1.2b) over cardiac muscle (CaV1.2a). Arterial vasodilator and antihypertensive agent.

Features and Benefits

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Ta strona może zawierać tekst przetłumaczony maszynowo.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Klasa składowania

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Jennifer L Herington et al.
PloS one, 10(11), e0143243-e0143243 (2015-11-26)
The uterine myometrium (UT-myo) is a therapeutic target for preterm labor, labor induction, and postpartum hemorrhage. Stimulation of intracellular Ca2+-release in UT-myo cells by oxytocin is a final pathway controlling myometrial contractions. The goal of this study was to develop
Tsuyoshi Shiga et al.
Heart and vessels, 22(6), 404-409 (2007-11-29)
The aim of this study was to investigate whether cilnidipine, an N- and L-type calcium channel blocker, and nisoldipine, an L-type calcium channel blocker, have different effects on sympathetic activity, using an identical group of healthy male subjects. Eight healthy
Xue-yan Chen et al.
Yao xue xue bao = Acta pharmaceutica Sinica, 43(10), 1011-1018 (2009-01-09)
Effect of new calcium antagonist m-nisoldipine (m-Nis) on MCT-induced PH in rats and its mechanisms were investigated. Rats were injected with a single dose (60 mg x kg(-1)) of MCT subcutaneously to induce PH. Pulmonary haemodynamic measurement and lung tissue
Piero Ruggenenti et al.
Nature reviews. Nephrology, 6(6), 319-330 (2010-05-05)
Angiotensin II and other components of the renin-angiotensin-aldosterone system (RAAS) have a central role in the pathogenesis and progression of diabetic renal disease. A study in patients with type 1 diabetes and overt nephropathy found that RAAS inhibition with angiotensin-converting-enzyme
Engineering of human cardiac muscle electromechanically matured to an adult-like phenotype
Ronaldson B K, et al.
Nature Protocols, 14(10), 2781-2817 (2019)

Produkty

We offers many products related to calcium channels for your research needs.

Powiązane treści

Numer pozycji handlu globalnego

SKUNUMER GTIN
N0165-50MG04061832962184
N0165-10MG04061832962177

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej